Are you over 18 and want to see adult content?
More Annotations
A complete backup of snapuptickets.com
Are you over 18 and want to see adult content?
A complete backup of nefurnituremarket.com
Are you over 18 and want to see adult content?
A complete backup of socialchorus.com
Are you over 18 and want to see adult content?
A complete backup of weareexplorers.co
Are you over 18 and want to see adult content?
A complete backup of nasty-angels.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of sokolowmusic.com
Are you over 18 and want to see adult content?
A complete backup of icaoti-my.sharepoint.com
Are you over 18 and want to see adult content?
A complete backup of cambridge-mt.com
Are you over 18 and want to see adult content?
Text
US
As a global leader in influenza protection, Seqirus has one of the broadest influenza vaccine portfolios in the world. In the Asia Pacific region we also provide access to a wide range of vaccines and specialty medicines that meet unique, local public health needs. Here you will find a listing of our products available around the globe. SEQIRUS WILL BUILD WORLD CLASS VACCINE MANUFACTURING FACILITY Seqirus will build the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere – producing seasonal and pandemic flu vaccines, Seqirus’ proprietary adjuvant MF59 ®, Australian antivenoms and Q-Fever vaccine.; The facility will be built in Tullamarine, in the Melbourne Airport Business Park, and expected to be operational in 2026. SEQIRUS | ANNUAL DISCLOSURES Seqirus is committed to workforce diversity and equity, as detailed in our Code of Responsible Business Practice. In accordance with UK regulations, Seqirus discloses gender pay gap information relating to our UK operations.Our first report covered 2017. SEQIRUS OPENS NEW CENTRE OF EXCELLENCE IN AMSTERDAM Seqirus, a global leader in influenza prevention, has officially opened its new European Centre of Excellence for Research & Development (R&D) and Quality in the Amsterdam-Zuidoost district of Amsterdam.. The €10 million centre of excellence, which includes office space and a new Quality laboratory, will be overseen by Amsterdam Managing Director, Mendel Haag.HOME | SEQIRUS US
The first and only cell-based quadrivalent influenza vaccine in the US that offers prevention against 4 influenza strains – virus subtypes A and type B contained within the vaccine -for people 4 THE SEQIRUS PORTFOLIO OF INFLUENZA VACCINES 2020-2021 … FLUAD ® (Influenza Vaccine, Adjuvanted), FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted), AFLURIA ® QUADRIVALENT (Influenza Vaccine), and FLUCELVAX QUADRIVALENT (Influenza Vaccine) INDICATION and IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for active CORPORATE GOVERNANCE Code of Responsible Business Practice. CSL aspires to maintain high standards of business practice and be a responsible employer and this Code is intended to set out the minimum standards applicable to our employees across the world. CSL’s legal obligations will be consistent with those that are applicable under local laws.LOGIN | SEQIRUS US
Note: For this order, you can only include Shipping Locations that are already confirmed on your Seqirus account. To add a new Shipping Location to your account, click "Add New Location" below. Our team will review and approve the new location, which can take up to 5business days.
INFLUENZA VACCINE RETURNS INFLUENZA VACCINE RETURNS FREQUENTLY ASKED QUESTIONS . Q: Where should I send my returns? A: Seqirus uses Inmar Pharmaceutical Services for all of its influenza vaccine returns. SEQIRUS | A WORLD LEADER IN INFLUENZA VACCINESOUR COMPANYEXPERTISER&DMANUFACTURINGPRODUCTSCAREERS Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS | OUR PRODUCTSALL PRODUCTSCOOKIE POLICYQUALITY & SAFETYCONTACTUS
As a global leader in influenza protection, Seqirus has one of the broadest influenza vaccine portfolios in the world. In the Asia Pacific region we also provide access to a wide range of vaccines and specialty medicines that meet unique, local public health needs. Here you will find a listing of our products available around the globe. SEQIRUS WILL BUILD WORLD CLASS VACCINE MANUFACTURING FACILITY Seqirus will build the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere – producing seasonal and pandemic flu vaccines, Seqirus’ proprietary adjuvant MF59 ®, Australian antivenoms and Q-Fever vaccine.; The facility will be built in Tullamarine, in the Melbourne Airport Business Park, and expected to be operational in 2026. SEQIRUS | ANNUAL DISCLOSURES Seqirus is committed to workforce diversity and equity, as detailed in our Code of Responsible Business Practice. In accordance with UK regulations, Seqirus discloses gender pay gap information relating to our UK operations.Our first report covered 2017. SEQIRUS OPENS NEW CENTRE OF EXCELLENCE IN AMSTERDAM Seqirus, a global leader in influenza prevention, has officially opened its new European Centre of Excellence for Research & Development (R&D) and Quality in the Amsterdam-Zuidoost district of Amsterdam.. The €10 million centre of excellence, which includes office space and a new Quality laboratory, will be overseen by Amsterdam Managing Director, Mendel Haag.HOME | SEQIRUS US
The first and only cell-based quadrivalent influenza vaccine in the US that offers prevention against 4 influenza strains – virus subtypes A and type B contained within the vaccine -for people 4 THE SEQIRUS PORTFOLIO OF INFLUENZA VACCINES 2020-2021 … FLUAD ® (Influenza Vaccine, Adjuvanted), FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted), AFLURIA ® QUADRIVALENT (Influenza Vaccine), and FLUCELVAX QUADRIVALENT (Influenza Vaccine) INDICATION and IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for active CORPORATE GOVERNANCE Code of Responsible Business Practice. CSL aspires to maintain high standards of business practice and be a responsible employer and this Code is intended to set out the minimum standards applicable to our employees across the world. CSL’s legal obligations will be consistent with those that are applicable under local laws.LOGIN | SEQIRUS US
Note: For this order, you can only include Shipping Locations that are already confirmed on your Seqirus account. To add a new Shipping Location to your account, click "Add New Location" below. Our team will review and approve the new location, which can take up to 5business days.
INFLUENZA VACCINE RETURNS INFLUENZA VACCINE RETURNS FREQUENTLY ASKED QUESTIONS . Q: Where should I send my returns? A: Seqirus uses Inmar Pharmaceutical Services for all of its influenza vaccine returns. SEQIRUS | OUR PRODUCTS As a global leader in influenza protection, Seqirus has one of the broadest influenza vaccine portfolios in the world. In the Asia Pacific region we also provide access to a wide range of vaccines and specialty medicines that meet unique, local public health needs. Here you will find a listing of our products available around the globe.SEQIRUS | ABOUT US
Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS | CONTACT US Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS | CAREER OPPORTUNITIES A clear vision for fighting disease in the 21st century, driven by more than 100 years of experience in combatting influenza and other serious diseases. Seqirus is empowered by the global strength of our parent company, CSL Limited. When you join Seqirus, you join a team dedicated to protecting people and communities from the influenza. FIRST ADJUVANTED QUADRIVALENT INFLUENZA VACCINE RECEIVES Maidenhead, UK 08 Jun 2020. news. The European Commission has today given regulatory approval for the first adjuvanted quadrivalent influenza vaccine to become available across Europe. This new vaccine builds on the well-established technology used in an existing adjuvanted trivalent influenza vaccine (aTIV) available in severalEuropean
SEQIRUS | WORLDWIDE DIRECTORY Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS OPENS NEW CENTRE OF EXCELLENCE IN AMSTERDAM Seqirus, a global leader in influenza prevention, has officially opened its new European Centre of Excellence for Research & Development (R&D) and Quality in the Amsterdam-Zuidoost district of Amsterdam.. The €10 million centre of excellence, which includes office space and a new Quality laboratory, will be overseen by Amsterdam Managing Director, Mendel Haag. SEQIRUS ANNOUNCES U.S. $140 MILLION MANUFACTURING Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia.ALL PRODUCTS
The first-and-only adjuvanted quadrivalent seasonal influenza vaccine approved for use in adults 65 years and older. 1 FLUAD QUADRIVALENT is manufactured using MF59® adjuvant technology, which is specifically designed to strengthen, broaden and lengthen the duration of the immune response. 2,3. 0.5 mL prefilled syringe. RESOURCES | SEQIRUS US Flu Clinic Resource Toolkit - Reducing Flu Burden During COVID Pandemic. Download this toolkit for materials to help educate patients on the importance of reducing the flu burden during the COVID pandemic. Assets include a poster, clinic signage, email template, patient outreach tools, and other essentials for your flu clinic. SEQIRUS | A WORLD LEADER IN INFLUENZA VACCINESOUR COMPANYEXPERTISER&DMANUFACTURINGPRODUCTSCAREERS Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS | CAREER OPPORTUNITIES A clear vision for fighting disease in the 21st century, driven by more than 100 years of experience in combatting influenza and other serious diseases. Seqirus is empowered by the global strength of our parent company, CSL Limited. When you join Seqirus, you join a team dedicated to protecting people and communities from the influenza. SEQIRUS OPENS NEW CENTRE OF EXCELLENCE IN AMSTERDAM Seqirus, a global leader in influenza prevention, has officially opened its new European Centre of Excellence for Research & Development (R&D) and Quality in the Amsterdam-Zuidoost district of Amsterdam.. The €10 million centre of excellence, which includes office space and a new Quality laboratory, will be overseen by Amsterdam Managing Director, Mendel Haag. SEQIRUS | ANNUAL DISCLOSURES Seqirus is committed to workforce diversity and equity, as detailed in our Code of Responsible Business Practice. In accordance with UK regulations, Seqirus discloses gender pay gap information relating to our UK operations.Our first report covered 2017. FIRST ADJUVANTED QUADRIVALENT INFLUENZA VACCINE RECEIVES Maidenhead, UK 08 Jun 2020. news. The European Commission has today given regulatory approval for the first adjuvanted quadrivalent influenza vaccine to become available across Europe. This new vaccine builds on the well-established technology used in an existing adjuvanted trivalent influenza vaccine (aTIV) available in severalEuropean
HOME | SEQIRUS US
The first and only cell-based quadrivalent influenza vaccine in the US that offers prevention against 4 influenza strains – virus subtypes A and type B contained within the vaccine -for people 4 CORPORATE GOVERNANCE Code of Responsible Business Practice. CSL aspires to maintain high standards of business practice and be a responsible employer and this Code is intended to set out the minimum standards applicable to our employees across the world. CSL’s legal obligations will be consistent with those that are applicable under local laws. THE SEQIRUS PORTFOLIO OF INFLUENZA VACCINES 2020-2021 … FLUAD ® (Influenza Vaccine, Adjuvanted), FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted), AFLURIA ® QUADRIVALENT (Influenza Vaccine), and FLUCELVAX QUADRIVALENT (Influenza Vaccine) INDICATION and IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for activeLOGIN | SEQIRUS US
Note: For this order, you can only include Shipping Locations that are already confirmed on your Seqirus account. To add a new Shipping Location to your account, click "Add New Location" below. Our team will review and approve the new location, which can take up to 5business days.
SHARON MCHALE
Sharon McHale joined the CSL Group in 2007 to establish the global Sustainability and Corporate Responsibility across the CSL enterprise. In 2010, she was appointed Senior Director, Public Affairs for CSL Limited in Australia, with her remit expanding in 2013 to include public policy. Sharon relocated to the UK in 2016 to join Seqirus as SEQIRUS | A WORLD LEADER IN INFLUENZA VACCINESOUR COMPANYEXPERTISER&DMANUFACTURINGPRODUCTSCAREERS Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS | CAREER OPPORTUNITIES A clear vision for fighting disease in the 21st century, driven by more than 100 years of experience in combatting influenza and other serious diseases. Seqirus is empowered by the global strength of our parent company, CSL Limited. When you join Seqirus, you join a team dedicated to protecting people and communities from the influenza. SEQIRUS OPENS NEW CENTRE OF EXCELLENCE IN AMSTERDAM Seqirus, a global leader in influenza prevention, has officially opened its new European Centre of Excellence for Research & Development (R&D) and Quality in the Amsterdam-Zuidoost district of Amsterdam.. The €10 million centre of excellence, which includes office space and a new Quality laboratory, will be overseen by Amsterdam Managing Director, Mendel Haag. SEQIRUS | ANNUAL DISCLOSURES Seqirus is committed to workforce diversity and equity, as detailed in our Code of Responsible Business Practice. In accordance with UK regulations, Seqirus discloses gender pay gap information relating to our UK operations.Our first report covered 2017. FIRST ADJUVANTED QUADRIVALENT INFLUENZA VACCINE RECEIVES Maidenhead, UK 08 Jun 2020. news. The European Commission has today given regulatory approval for the first adjuvanted quadrivalent influenza vaccine to become available across Europe. This new vaccine builds on the well-established technology used in an existing adjuvanted trivalent influenza vaccine (aTIV) available in severalEuropean
HOME | SEQIRUS US
The first and only cell-based quadrivalent influenza vaccine in the US that offers prevention against 4 influenza strains – virus subtypes A and type B contained within the vaccine -for people 4 CORPORATE GOVERNANCE Code of Responsible Business Practice. CSL aspires to maintain high standards of business practice and be a responsible employer and this Code is intended to set out the minimum standards applicable to our employees across the world. CSL’s legal obligations will be consistent with those that are applicable under local laws. THE SEQIRUS PORTFOLIO OF INFLUENZA VACCINES 2020-2021 … FLUAD ® (Influenza Vaccine, Adjuvanted), FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted), AFLURIA ® QUADRIVALENT (Influenza Vaccine), and FLUCELVAX QUADRIVALENT (Influenza Vaccine) INDICATION and IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for activeLOGIN | SEQIRUS US
Note: For this order, you can only include Shipping Locations that are already confirmed on your Seqirus account. To add a new Shipping Location to your account, click "Add New Location" below. Our team will review and approve the new location, which can take up to 5business days.
SHARON MCHALE
Sharon McHale joined the CSL Group in 2007 to establish the global Sustainability and Corporate Responsibility across the CSL enterprise. In 2010, she was appointed Senior Director, Public Affairs for CSL Limited in Australia, with her remit expanding in 2013 to include public policy. Sharon relocated to the UK in 2016 to join Seqirus asSEQIRUS | ABOUT US
Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS ANNOUNCES U.S. $140 MILLION MANUFACTURING Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. RESOURCES | SEQIRUS US Flu Clinic Resource Toolkit - Reducing Flu Burden During COVID Pandemic. Download this toolkit for materials to help educate patients on the importance of reducing the flu burden during the COVID pandemic. Assets include a poster, clinic signage, email template, patient outreach tools, and other essentials for your flu clinic. THE SEQIRUS PORTFOLIO OF INFLUENZA VACCINES 2020-2021 … FLUAD ® (Influenza Vaccine, Adjuvanted), FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted), AFLURIA ® QUADRIVALENT (Influenza Vaccine), and FLUCELVAX QUADRIVALENT (Influenza Vaccine) INDICATION and IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for activeSHARON MCHALE
Sharon McHale joined the CSL Group in 2007 to establish the global Sustainability and Corporate Responsibility across the CSL enterprise. In 2010, she was appointed Senior Director, Public Affairs for CSL Limited in Australia, with her remit expanding in 2013 to include public policy. Sharon relocated to the UK in 2016 to join Seqirus asGYURI ENDES
Gyuri was formally appointed to Vice President, Human Resources for Seqirus in May 2019. He moves from our parent company, CSL, where he led the Human Resources Business Partner organisation. Prior to this, Gyuri was Head of HR Supply Chain Switzerland with Johnson & Johnson. He started his career in the pharmaceutical industry in 1994 and held MAJOR UK INVESTMENT TO BOOST INFLUENZA VACCINE PRODUCTION The £40m project announced today takes the company’s investment in the site to over £60m since CSL acquired the Novartis influenza vaccine business in July 2015 to create Seqirus. Business Secretary Greg Clark said: “Through the Industrial Strategy, the Government is building on our world-leading strengths in research and innovation,and
CONSUMER MEDICINE INFORMATION RYALTRIS® NASAL SPRAY Page 1 of 6 RYALTRIS® Nasal Spray (rye – al’ – tris) Olopatadine hydrochloride and mometasone furoate monohydrate. CONSUMER MEDICINEASSYSTNET
assystNET
FLUCELVAX QUADRIVALENT (INFLUENZA VACCINE) CODING AND BILLING NDC=National Drug Code Note: Some payers may require use of NDCs. If so, determine if the payer requires the carton NDC or the unit-of-use NDC, and then determine SEQIRUS | A WORLD LEADER IN INFLUENZA VACCINESOUR COMPANYEXPERTISER&DMANUFACTURINGPRODUCTSCAREERS Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS | CAREER OPPORTUNITIES A clear vision for fighting disease in the 21st century, driven by more than 100 years of experience in combatting influenza and other serious diseases. Seqirus is empowered by the global strength of our parent company, CSL Limited. When you join Seqirus, you join a team dedicated to protecting people and communities from the influenza. SEQIRUS OPENS NEW CENTRE OF EXCELLENCE IN AMSTERDAM Seqirus, a global leader in influenza prevention, has officially opened its new European Centre of Excellence for Research & Development (R&D) and Quality in the Amsterdam-Zuidoost district of Amsterdam.. The €10 million centre of excellence, which includes office space and a new Quality laboratory, will be overseen by Amsterdam Managing Director, Mendel Haag. SEQIRUS | ANNUAL DISCLOSURES Seqirus is committed to workforce diversity and equity, as detailed in our Code of Responsible Business Practice. In accordance with UK regulations, Seqirus discloses gender pay gap information relating to our UK operations.Our first report covered 2017. FIRST ADJUVANTED QUADRIVALENT INFLUENZA VACCINE RECEIVES Maidenhead, UK 08 Jun 2020. news. The European Commission has today given regulatory approval for the first adjuvanted quadrivalent influenza vaccine to become available across Europe. This new vaccine builds on the well-established technology used in an existing adjuvanted trivalent influenza vaccine (aTIV) available in severalEuropean
HOME | SEQIRUS US
The first and only cell-based quadrivalent influenza vaccine in the US that offers prevention against 4 influenza strains – virus subtypes A and type B contained within the vaccine -for people 4 CORPORATE GOVERNANCE Code of Responsible Business Practice. CSL aspires to maintain high standards of business practice and be a responsible employer and this Code is intended to set out the minimum standards applicable to our employees across the world. CSL’s legal obligations will be consistent with those that are applicable under local laws. THE SEQIRUS PORTFOLIO OF INFLUENZA VACCINES 2020-2021 … FLUAD ® (Influenza Vaccine, Adjuvanted), FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted), AFLURIA ® QUADRIVALENT (Influenza Vaccine), and FLUCELVAX QUADRIVALENT (Influenza Vaccine) INDICATION and IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for activeLOGIN | SEQIRUS US
Note: For this order, you can only include Shipping Locations that are already confirmed on your Seqirus account. To add a new Shipping Location to your account, click "Add New Location" below. Our team will review and approve the new location, which can take up to 5business days.
SHARON MCHALE
Sharon McHale joined the CSL Group in 2007 to establish the global Sustainability and Corporate Responsibility across the CSL enterprise. In 2010, she was appointed Senior Director, Public Affairs for CSL Limited in Australia, with her remit expanding in 2013 to include public policy. Sharon relocated to the UK in 2016 to join Seqirus as SEQIRUS | A WORLD LEADER IN INFLUENZA VACCINESOUR COMPANYEXPERTISER&DMANUFACTURINGPRODUCTSCAREERS Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS | CAREER OPPORTUNITIES A clear vision for fighting disease in the 21st century, driven by more than 100 years of experience in combatting influenza and other serious diseases. Seqirus is empowered by the global strength of our parent company, CSL Limited. When you join Seqirus, you join a team dedicated to protecting people and communities from the influenza. SEQIRUS OPENS NEW CENTRE OF EXCELLENCE IN AMSTERDAM Seqirus, a global leader in influenza prevention, has officially opened its new European Centre of Excellence for Research & Development (R&D) and Quality in the Amsterdam-Zuidoost district of Amsterdam.. The €10 million centre of excellence, which includes office space and a new Quality laboratory, will be overseen by Amsterdam Managing Director, Mendel Haag. SEQIRUS | ANNUAL DISCLOSURES Seqirus is committed to workforce diversity and equity, as detailed in our Code of Responsible Business Practice. In accordance with UK regulations, Seqirus discloses gender pay gap information relating to our UK operations.Our first report covered 2017. FIRST ADJUVANTED QUADRIVALENT INFLUENZA VACCINE RECEIVES Maidenhead, UK 08 Jun 2020. news. The European Commission has today given regulatory approval for the first adjuvanted quadrivalent influenza vaccine to become available across Europe. This new vaccine builds on the well-established technology used in an existing adjuvanted trivalent influenza vaccine (aTIV) available in severalEuropean
HOME | SEQIRUS US
The first and only cell-based quadrivalent influenza vaccine in the US that offers prevention against 4 influenza strains – virus subtypes A and type B contained within the vaccine -for people 4 CORPORATE GOVERNANCE Code of Responsible Business Practice. CSL aspires to maintain high standards of business practice and be a responsible employer and this Code is intended to set out the minimum standards applicable to our employees across the world. CSL’s legal obligations will be consistent with those that are applicable under local laws. THE SEQIRUS PORTFOLIO OF INFLUENZA VACCINES 2020-2021 … FLUAD ® (Influenza Vaccine, Adjuvanted), FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted), AFLURIA ® QUADRIVALENT (Influenza Vaccine), and FLUCELVAX QUADRIVALENT (Influenza Vaccine) INDICATION and IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for activeLOGIN | SEQIRUS US
Note: For this order, you can only include Shipping Locations that are already confirmed on your Seqirus account. To add a new Shipping Location to your account, click "Add New Location" below. Our team will review and approve the new location, which can take up to 5business days.
SHARON MCHALE
Sharon McHale joined the CSL Group in 2007 to establish the global Sustainability and Corporate Responsibility across the CSL enterprise. In 2010, she was appointed Senior Director, Public Affairs for CSL Limited in Australia, with her remit expanding in 2013 to include public policy. Sharon relocated to the UK in 2016 to join Seqirus asSEQIRUS | ABOUT US
Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS ANNOUNCES U.S. $140 MILLION MANUFACTURING Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. RESOURCES | SEQIRUS US Flu Clinic Resource Toolkit - Reducing Flu Burden During COVID Pandemic. Download this toolkit for materials to help educate patients on the importance of reducing the flu burden during the COVID pandemic. Assets include a poster, clinic signage, email template, patient outreach tools, and other essentials for your flu clinic. THE SEQIRUS PORTFOLIO OF INFLUENZA VACCINES 2020-2021 … FLUAD ® (Influenza Vaccine, Adjuvanted), FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted), AFLURIA ® QUADRIVALENT (Influenza Vaccine), and FLUCELVAX QUADRIVALENT (Influenza Vaccine) INDICATION and IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for activeSHARON MCHALE
Sharon McHale joined the CSL Group in 2007 to establish the global Sustainability and Corporate Responsibility across the CSL enterprise. In 2010, she was appointed Senior Director, Public Affairs for CSL Limited in Australia, with her remit expanding in 2013 to include public policy. Sharon relocated to the UK in 2016 to join Seqirus asGYURI ENDES
Gyuri was formally appointed to Vice President, Human Resources for Seqirus in May 2019. He moves from our parent company, CSL, where he led the Human Resources Business Partner organisation. Prior to this, Gyuri was Head of HR Supply Chain Switzerland with Johnson & Johnson. He started his career in the pharmaceutical industry in 1994 and held MAJOR UK INVESTMENT TO BOOST INFLUENZA VACCINE PRODUCTION The £40m project announced today takes the company’s investment in the site to over £60m since CSL acquired the Novartis influenza vaccine business in July 2015 to create Seqirus. Business Secretary Greg Clark said: “Through the Industrial Strategy, the Government is building on our world-leading strengths in research and innovation,and
CONSUMER MEDICINE INFORMATION RYALTRIS® NASAL SPRAY Page 1 of 6 RYALTRIS® Nasal Spray (rye – al’ – tris) Olopatadine hydrochloride and mometasone furoate monohydrate. CONSUMER MEDICINEASSYSTNET
assystNET
FLUCELVAX QUADRIVALENT (INFLUENZA VACCINE) CODING AND BILLING NDC=National Drug Code Note: Some payers may require use of NDCs. If so, determine if the payer requires the carton NDC or the unit-of-use NDC, and then determine SEQIRUS | A WORLD LEADER IN INFLUENZA VACCINESOUR COMPANYEXPERTISER&DMANUFACTURINGPRODUCTSCAREERS Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS | OUR PRODUCTSALL PRODUCTSCOOKIE POLICYQUALITY & SAFETYCONTACTUS
As a global leader in influenza protection, Seqirus has one of the broadest influenza vaccine portfolios in the world. In the Asia Pacific region we also provide access to a wide range of vaccines and specialty medicines that meet unique, local public health needs. Here you will find a listing of our products available around the globe.SEQIRUS | ABOUT US
Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS | CONTACT US Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS | CAREER OPPORTUNITIES A clear vision for fighting disease in the 21st century, driven by more than 100 years of experience in combatting influenza and other serious diseases. Seqirus is empowered by the global strength of our parent company, CSL Limited. When you join Seqirus, you join a team dedicated to protecting people and communities from the influenza. SEQIRUS OPENS NEW CENTRE OF EXCELLENCE IN AMSTERDAM Seqirus, a global leader in influenza prevention, has officially opened its new European Centre of Excellence for Research & Development (R&D) and Quality in the Amsterdam-Zuidoost district of Amsterdam.. The €10 million centre of excellence, which includes office space and a new Quality laboratory, will be overseen by Amsterdam Managing Director, Mendel Haag. SEQIRUS | ANNUAL DISCLOSURES Seqirus is committed to workforce diversity and equity, as detailed in our Code of Responsible Business Practice. In accordance with UK regulations, Seqirus discloses gender pay gap information relating to our UK operations.Our first report covered 2017.HOME | SEQIRUS US
The first and only cell-based quadrivalent influenza vaccine in the US that offers prevention against 4 influenza strains – virus subtypes A and type B contained within the vaccine -for people 4 THE SEQIRUS PORTFOLIO OF INFLUENZA VACCINES 2020-2021 … FLUAD ® (Influenza Vaccine, Adjuvanted), FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted), AFLURIA ® QUADRIVALENT (Influenza Vaccine), and FLUCELVAX QUADRIVALENT (Influenza Vaccine) INDICATION and IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for activeLOGIN | SEQIRUS US
Note: For this order, you can only include Shipping Locations that are already confirmed on your Seqirus account. To add a new Shipping Location to your account, click "Add New Location" below. Our team will review and approve the new location, which can take up to 5business days.
SEQIRUS | A WORLD LEADER IN INFLUENZA VACCINESOUR COMPANYEXPERTISER&DMANUFACTURINGPRODUCTSCAREERS Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS | OUR PRODUCTSALL PRODUCTSCOOKIE POLICYQUALITY & SAFETYCONTACTUS
As a global leader in influenza protection, Seqirus has one of the broadest influenza vaccine portfolios in the world. In the Asia Pacific region we also provide access to a wide range of vaccines and specialty medicines that meet unique, local public health needs. Here you will find a listing of our products available around the globe.SEQIRUS | ABOUT US
Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS | CONTACT US Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS | CAREER OPPORTUNITIES A clear vision for fighting disease in the 21st century, driven by more than 100 years of experience in combatting influenza and other serious diseases. Seqirus is empowered by the global strength of our parent company, CSL Limited. When you join Seqirus, you join a team dedicated to protecting people and communities from the influenza. SEQIRUS OPENS NEW CENTRE OF EXCELLENCE IN AMSTERDAM Seqirus, a global leader in influenza prevention, has officially opened its new European Centre of Excellence for Research & Development (R&D) and Quality in the Amsterdam-Zuidoost district of Amsterdam.. The €10 million centre of excellence, which includes office space and a new Quality laboratory, will be overseen by Amsterdam Managing Director, Mendel Haag. SEQIRUS | ANNUAL DISCLOSURES Seqirus is committed to workforce diversity and equity, as detailed in our Code of Responsible Business Practice. In accordance with UK regulations, Seqirus discloses gender pay gap information relating to our UK operations.Our first report covered 2017.HOME | SEQIRUS US
The first and only cell-based quadrivalent influenza vaccine in the US that offers prevention against 4 influenza strains – virus subtypes A and type B contained within the vaccine -for people 4 THE SEQIRUS PORTFOLIO OF INFLUENZA VACCINES 2020-2021 … FLUAD ® (Influenza Vaccine, Adjuvanted), FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted), AFLURIA ® QUADRIVALENT (Influenza Vaccine), and FLUCELVAX QUADRIVALENT (Influenza Vaccine) INDICATION and IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for activeLOGIN | SEQIRUS US
Note: For this order, you can only include Shipping Locations that are already confirmed on your Seqirus account. To add a new Shipping Location to your account, click "Add New Location" below. Our team will review and approve the new location, which can take up to 5business days.
SEQIRUS | OUR PRODUCTS As a global leader in influenza protection, Seqirus has one of the broadest influenza vaccine portfolios in the world. In the Asia Pacific region we also provide access to a wide range of vaccines and specialty medicines that meet unique, local public health needs. Here you will find a listing of our products available around the globe. SEQIRUS | CONTACT US Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS WILL BUILD WORLD CLASS VACCINE MANUFACTURING FACILITY Seqirus will build the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere – producing seasonal and pandemic flu vaccines, Seqirus’ proprietary adjuvant MF59 ®, Australian antivenoms and Q-Fever vaccine.; The facility will be built in Tullamarine, in the Melbourne Airport Business Park, and expected to be operational in 2026. SEQIRUS | WORLDWIDE DIRECTORY Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. SEQIRUS | MEET OUR LEADERSHIP Seqirus shares the CSL Group Values which have guided the company for many decades. Our Values are fundamental to our success — helping us to save lives, protect the health of people, and earn our reputation as a trusted and reliable global leader. They’re at the core of how our employees interact with others, make decisions and solve problems. THE SEQIRUS PORTFOLIO OF INFLUENZA VACCINES 2020-2021 … FLUAD ® (Influenza Vaccine, Adjuvanted), FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted), AFLURIA ® QUADRIVALENT (Influenza Vaccine), and FLUCELVAX QUADRIVALENT (Influenza Vaccine) INDICATION and IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for active RESOURCES | SEQIRUS US Flu Clinic Resource Toolkit - Reducing Flu Burden During COVID Pandemic. Download this toolkit for materials to help educate patients on the importance of reducing the flu burden during the COVID pandemic. Assets include a poster, clinic signage, email template, patient outreach tools, and other essentials for your flu clinic.SHARON MCHALE
Sharon McHale joined the CSL Group in 2007 to establish the global Sustainability and Corporate Responsibility across the CSL enterprise. In 2010, she was appointed Senior Director, Public Affairs for CSL Limited in Australia, with her remit expanding in 2013 to include public policy. Sharon relocated to the UK in 2016 to join Seqirus as FLU VACCINATION IS AN ESSENTIAL PUBLIC HEALTH TOOL The COVID-19 pandemic has presented the healthcare system with unprecedented challenges. A second wave of COVID-19 may hit this fall during the influenza season, which could possibly result in an INFLUENZA VACCINE RETURNS INFLUENZA VACCINE RETURNS FREQUENTLY ASKED QUESTIONS . Q: Where should I send my returns? A: Seqirus uses Inmar Pharmaceutical Services for all of its influenza vaccine returns. Skip to main content * Global Selector __*
* News
* Partnering
* Contact
*
Our Company
Our Company__
Corporate Responsibility__ Corporate Responsibility__Disclosures__
Leadership__
Derived from the expression 'securing health for all of us', Seqirus has public health protection at its core.Learn more
At Seqirus, Corporate Responsibility is about conducting our business ethically and contributing to the economic, social and environmental well-being of our communities.Learn more
*
Expertise
Expertise__
Influenza__
Influenza__
Pandemic Response Solutions__ Antivenom & Q fever Vaccines__In-licensing__
Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia.Learn more
Seqirus is on the front line of battling influenza, working hard to suppress costly and life-threatening epidemics and pandemics. Vaccination is the most effective way to prevent influenza .Learn more
*
R&D
R&D__
Research Practices__ Investigator Initiated Studies__ Seqirus Young Scientist Innovative Award__ Our Seqirus research and development group provides support to ensure the conditions are optimised for efficient vaccine manufacture. Activities also focus on improving the effectiveness of current influenza vaccines and their manufacturing processes.Learn more
At Seqirus, we are committed to carrying out R&D in an ethical and transparent way as well as in accordance with government regulations and industry codes for good practice.Learn more
*
Manufacturing
Manufacturing__
Global Manufacturing Network__Technologies__
Technical Development__Quality & Safety__
One of the largest influenza vaccine companies in the world, Seqirus operates state-of-the-art manufacturing facilities in three different continents and a globally integrated supply chain for the timely supply of influenza vaccine to customers around the world.Learn more
Seqirus utilises both egg and cell-based production technologies and we offer a broadest portfolio of influenza vaccines. We have commercialised the only adjuvanted seasonal influenza vaccine for older adults and paediatrics and offer two different types of quadrivalent influenza vaccines.Learn more
*
Products
*
Careers
Careers__
See Yourself at Seqirus__ Discover Our People__ Diversity and Inclusion__ How we care for you at Seqirus__ When you join Seqirus, you join a team dedicated to protecting people and communities from influenza. It's a feeling of purpose and possibility that inspires us every day.Learn more
It doesn't matter whether you are a scientist or an administrator, a marketer or an operator - as long as you are inspired by the chance to create something that will help others, you can find your role atSeqirus.
Learn more
* __
* __
* __
Seqirus
__ __Back
*
Our Company __
*
Our Company __
*
Corporate Responsibility __*
Corporate Responsibility __*
Disclosures __
*
Leadership __
*
Expertise __
*
Expertise __
*
Influenza __
*
Influenza __
*
Pandemic Response Solutions __*
Antivenom & Q fever Vaccines __*
In-licensing __
*
R&D __
*
R&D __
*
Research Practices __*
Investigator Initiated Studies __*
Seqirus Young Scientist Innovative Award __*
Manufacturing __
*
Manufacturing __
*
Global Manufacturing Network __*
Technologies __
*
Technical Development __*
Quality & Safety __
*
Products __
*
Careers __
*
Careers __
*
See Yourself at Seqirus __*
Discover Our People __*
Diversity and Inclusion __*
How we care for you at Seqirus __*
News
*
Partnering
*
Contact
__
SEQIRUS WILL BUILD WORLD-CLASS, NEXT-GENERATION $800M INFLUENZA VACCINE MANUFACTURING FACILITY IN AUSTRALIALearn More
COVID-19 UPDATE: SAFEGUARDING OUR PEOPLE AND COMMUNITIES REMAINS OURTOP PRIORITY.
Learn More
WE ARE A GLOBAL FORCE IN THE FIGHT AGAINST INFLUENZA, ON THE FRONT LINE OF PROTECTION SINCE 1918. Watch our documentary__ __
SEQIRUS WILL BUILD WORLD-CLASS, NEXT-GENERATION $800M INFLUENZA VACCINE MANUFACTURING FACILITY IN AUSTRALIALearn More
COVID-19 UPDATE: SAFEGUARDING OUR PEOPLE AND COMMUNITIES REMAINS OURTOP PRIORITY.
Learn More
WE ARE A GLOBAL FORCE IN THE FIGHT AGAINST INFLUENZA, ON THE FRONT LINE OF PROTECTION SINCE 1918. Watch our documentary__
Popular search terms: * Influenza Vaccines* Careers
* Pandemic Preparedness* Expertise
COVID-19: A MESSAGE FROM OUR CEO "As the COVID-19 pandemic evolves, CSL remains committed to safeguarding our patients, our donors and our people. In keeping with our values-based culture, CSL has taken precautions to ensure our employees and our facilities remain safe so we can continue to deliver on our promise to patients and public health." - Paul Perreault, CEO & Managing Director, CSL Limited WE'RE COMMITTED TO THE FIGHT AGAINST INFLUENZA At Seqirus, we are driven by just one goal - to lessen the severity and impact of influenza, which can reach epidemic or even pandemic proportions with life-threatening consequences. Every year our influenza vaccines help protect millions of people. We find solutions to big, complex, challenging problems, and we see the results in the world around us. Then we do it all over again the following year. Seqirus is one of the world’s largest influenza vaccine companies. We were created when our parent company, CSL Limited, acquired the Novartis influenza vaccine business and combined it with vaccinesubsidiary, bioCSL.
100 YEARS OF SECURING HEALTHY LIVES Seqirus has a rich heritage in guarding against influenza. As part of CSL, our experience dates back to the deadly 1918 influenza pandemic and we’ve worked with global health partners on the front line of influenza protection ever since.Learn more
JOIN US ON THE FRONT LINE When you join Seqirus, you join a skilled and passionate team dedicated to protecting people and communities from influenza. It's the feeling of purpose and possibility that inspires us every day.Careers
This website is intended for people seeking information on Seqirus'worldwide business.
Our country sites can be located in our Worldwide Directory.
UK/FLU/0519/0080 August 2019Our Company
We are one of the world’s largest influenza vaccine companies with a unique singular focus on influenza.Learn more
Products
Our broad range of influenza vaccines help safeguard people and communities all around the globe.Learn more
Contact
There are many ways to contact us and connect to our offices aroundthe world.
Learn more
*
*
* Report an Adverse Event* Cookie Policy
* Privacy Statement
* Modern Slavery
* Terms of Use
* Sitemap
© 2020 Seqirus. All rights reserved. Seqirus is a trademark of Seqirus UK Limited or its affiliates. Popular search terms: * Influenza Vaccines* Careers
* Pandemic Preparedness* Expertise
__
Play
PausePlay
Seek% buffered00:00UnmuteMuteDisable captionsEnable captionsExit fullscreenEnter fullscreen __Corporate
* CSL Limited (Global)Seqirus
* Seqirus (Global)
* Seqirus (Australia) * Seqirus (New Zealand)* Seqirus (Germany)
* Seqirus (Italy)
* Seqirus (US)
* Seqirus (Argentina)* Seqirus (Canada)
__
This website uses cookies to ensure the best possible user experience. Please note that if you do not accept the cookies, your user experience may be significantly less positive. You will find more information on how to disable the use of cookies inour Cookie Policy .
__
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0